UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Frontiers in oncology, 2023-05, Vol.13, p.1163768-1163768

2023

Volltextzugriff (PDF)

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours

Endocrine Connections, 2017-11, Vol.6 (8), p.876-885

2017

Volltextzugriff (PDF)

Fatigue in non-small cell lung cancer (NSCLC) patients treated with immunotherapy, is there a role for physical activity?

Lung cancer (Amsterdam, Netherlands), 2021-06, Vol.156, p.S48

2021

Volltextzugriff (PDF)

Oncology and medical education-past, present and future

Ecancermedicalscience, 2016, Vol.10, p.ed54-ed54

Cave, Judith

2016

Volltextzugriff (PDF)

Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S53

2023

Volltextzugriff (PDF)

122 - Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S53-S53

2023

Volltextzugriff (PDF)

208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107769, Article 107769

2024

Volltextzugriff (PDF)

135 - Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S62-S62

2022

Volltextzugriff (PDF)

Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S62

2022

Volltextzugriff (PDF)

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS8600-TPS8600

2023

Volltextzugriff (PDF)

THE COMPETENT NOVICE: Dealing with complaints

BMJ. British medical journal (International ed.), 2008-02, Vol.336 (7639), p.326

International edition, 2008

Volltextzugriff (PDF)

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

International immunopharmacology, 2022-09, Vol.110, p.108985-108985, Article 108985

2022

Volltextzugriff (PDF)

76 - Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S33-S33

2023

Volltextzugriff (PDF)

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S33

2023

Volltextzugriff (PDF)

NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.646-646

2023

Volltextzugriff (PDF)

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS9138-TPS9138

2021

Volltextzugriff (PDF)

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4005-4005

2022

Volltextzugriff (PDF)

The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4110-4110

2021

Volltextzugriff (PDF)

84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107645, Article 107645

2024

Volltextzugriff (PDF)

Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

Nature (London), 2020-09, Vol.585 (7826), p.E21-E21

2020

Volltextzugriff (PDF)

The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis

BMJ open, 2019-08, Vol.9 (8), p.e031531-e031531

2019

Volltextzugriff (PDF)

Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.A115-A115

2023

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(67)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(11)
Oncology
(6)
Biological And Medical Sciences
(5)
General & Internal Medicine
(4)
Medicine, General & Internal
(4)
Patients
(4)
Complaints
(3)
Medical Sciences
(3)
Analysis
(2)
Animals
(2)
Docetaxel
(2)
Economic Policy
(2)
Fundamental And Applied Biological Sciences. Psychology
(2)
Gastroenterology And Hepatology
(2)
General Aspects
(2)
Liposomal Irinotecan
(2)
Litigation
(2)
Lung Cancer
(2)
Neuroendocrine Carcinoma
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours

Fatigue in non-small cell lung cancer (NSCLC) patients treated with immunotherapy, is there a role for physical activity?

Oncology and medical education-past, present and future

Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

122 - Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma

208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma

135 - Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital

A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO

THE COMPETENT NOVICE: Dealing with complaints

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

76 - Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC)

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON)

Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)

193 - Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS)

Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS)

The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results

84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer

Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer

The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis

Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

Aktive Filter

Suchergebnisse filtern